CandlesenseCandlesense
BBIO•benzinga•

BridgeBio Pharma Presented Initial Outcomes From The ATTRibute-CM Open-label Extension Study Of Acoramidis In ATTR-CM At The AHA Scientific Sessions; Acoramidis Demonstrated The Earliest Known Time To Separation In Cardiovascular Outcomes In The ATTRibut

Summary

No summary available.

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on November 18, 2024 by benzinga

← Back to BBIO News
    BridgeBio Pharma Presented Initial Outcomes From The ATTRibute-CM Open-label Extension Study Of Acoramidis In ATTR-CM At The AHA Scientific Sessions; Acoramidis Demonstrated The Earliest Known Time To Separation In Cardiovascular Outcomes In The ATTRibut | BBIO Stock News | Candlesense